Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Harvard Business School
Merck
Baxter
Express Scripts

Last Updated: May 25, 2022

Investigational Drug Information for AZD2014


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug AZD2014?

AZD2014 is an investigational drug.

There have been 33 clinical trials for AZD2014. The most recent clinical trial was a Phase 2 trial, which was initiated on April 23rd 2014.

The most common disease conditions in clinical trials are Lung Neoplasms, Breast Neoplasms, and Neoplasms. The leading clinical trial sponsors are AstraZeneca, Samsung Medical Center, and Cancer Research UK.

There are one hundred and fourteen US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for AZD2014
TitleSponsorPhase
Phase II Trial of Vistusertib´╝łAZD2014´╝ë Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard ChemotherapySamsung Medical CenterPhase 2
Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard ChemotherapySamsung Medical CenterPhase 2
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid TumorsNational Cancer Institute (NCI)Phase 1/Phase 2

See all AZD2014 clinical trials

Clinical Trial Summary for AZD2014

Top disease conditions for AZD2014
Top clinical trial sponsors for AZD2014

See all AZD2014 clinical trials

US Patents for AZD2014

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD2014 See Plans and Pricing Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH) See Plans and Pricing
AZD2014 See Plans and Pricing Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors KuDOS Pharmaceuticals Limited (London, GB) See Plans and Pricing
AZD2014 See Plans and Pricing 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]- pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy Oncoceutics, Inc. (Philadelphia, PA) See Plans and Pricing
AZD2014 See Plans and Pricing Heterocyclic estrogen receptor modulators and uses thereof Genentech, Inc. (South San Francisco, CA) See Plans and Pricing
AZD2014 See Plans and Pricing Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN) See Plans and Pricing
AZD2014 See Plans and Pricing mTORC1 inhibitors The Regents of the University of California (Oakland, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD2014

Drugname Country Document Number Estimated Expiration Related US Patent
AZD2014 Australia AU2014348657 2033-11-13 See Plans and Pricing
AZD2014 Australia AU2017245411 2033-11-13 See Plans and Pricing
AZD2014 Australia AU2019246853 2033-11-13 See Plans and Pricing
AZD2014 Brazil BR112016010716 2033-11-13 See Plans and Pricing
AZD2014 Canada CA2929181 2033-11-13 See Plans and Pricing
AZD2014 China CN105899232 2033-11-13 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Harvard Business School
Merck
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.